AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04812691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
Study NCT01468012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa carbidopa and entacapone (LCE)
Description: 400mg/100mg/200mg, twice daily
Study NCT01468012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo for LCE condition dosed twice daily
Study NCT04082312 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00713050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imitate Therapy
Description: Imitation-based computer therapy
Study NCT00713050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imitate Therapy
Description: Imitation-based computer therapy
Study NCT02376088 — intervention group
Intervention type: DRUG
Intervention: Methimazole
Description: All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
Study NCT02198274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBH 1
Description: 100 mg/week
Study NCT01192854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: Clevudine flexible dosages of 30 mg/day
Study NCT01192854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir flexible dosages of 10 mg/day
Study NCT00325728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
Study NCT00325728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
Study NCT01167894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study NCT01167894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study NCT02726204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance Alone
Description: CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
Study NCT02726204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance and Gravity Elimination
Study NCT02945943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude mobilization
Description: Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
Study NCT01712581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study NCT00652314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombi-Gel
Description: Applicaton of Hemostatic product during surgery
Study NCT00652314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombi-Gel
Description: Applicaton of Hemostatic product during surgery
Study NCT04052750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS follow-up
Description: In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
Study NCT02945943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.
Study NCT02945943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.
Study NCT01722214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
Study NCT01722214 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
Study NCT01722214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
Study NCT01855867 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Study NCT02525809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Novae E®
Study NCT02525809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sunfit®
Study NCT02525809 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quartz®
Study NCT02573012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to prednisone
Description: Participants will receive placebo matched to prednisone orally for 24 weeks.
Study NCT02573012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
Study NCT02573012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
Study NCT00113555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT (Adjustable Continence Therapy)
Description: surgically implanted device
Study NCT02934061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tizaspray® administered intranasally
Description: 0,5 mg Tizaspray® administered intranasally
Study NCT02934061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirdalud® 2 mg tablets administered
Description: Sirdalud® 2 mg tablets administered in patients with acute low back pain
Study NCT01518673 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
Study NCT02325089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
Study NCT02325089 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
Study NCT01922466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture
Description: Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week
Study NCT01922466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study NCT01376505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 vaccine
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738)
Description: 240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOCETAXEL
Description: 75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day
Study NCT03833440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg QD~1 cycle = 28 days
Study NCT01228669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0172-0000-2021
Description: Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
Study NCT01228669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0172-0000-2021
Description: Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
Study NCT01228669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
Study NCT04166916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic stimulation
Description: Acoustic stimulation to modulate slow waves.
Study NCT01376505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extension HER-2 vaccine trial at OBD
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
Study NCT02692560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STAND
Description: Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
Study NCT02692560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Description: Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Study NCT00728195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Study NCT01126281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halophites-based cream 24 hours
Description: The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Halophites-based cream 48 hours
Description: The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream 24 hours
Description: A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle cream 48 hours
Description: A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Histamine 1%
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
Study NCT04635254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cowhage
Description: The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study NCT00528411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Tablets
Description: Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
Study NCT01753986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention plus Standard Batterer Intervention
Description: Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
Study NCT01753986 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Improvement Intervention plus Standard Batterer Intervention
Description: General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
Study NCT00528411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel (over encapsulated) capsule
Description: Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
Study NCT00528411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Tablets
Description: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
Study NCT00528411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablets
Description: Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
Study NCT03745872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Assessment
Description: Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
Study NCT02283905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: amphotericin-B
Description: continuously infused
Study NCT02283905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: voriconazole
Description: intravenously or orally administered
Study NCT00784888 — intervention group
Intervention type: OTHER
Intervention: Aromatase inhibitors
Description: non-interventional study
Study NCT01032603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral lateral rectus recession (BLRc)
Description: Bilateral lateral rectus recession surgery
Study NCT01032603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral lateral rectus recession with medial rectus resection (R&R)
Description: A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
Study NCT02562300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
Study NCT02562300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
Study NCT02209792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02209792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02209792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 5 mg
Study NCT02209792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS, 20 mg
Study NCT00191945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Study NCT00191945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Study NCT00191945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02777203 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EcoSac 400 ECO-T
Description: Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
Study NCT02763813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst (propulsion type oral appliance)
Description: Oral appliance
Study NCT02763813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retention type appliance (ORM)
Study NCT04905524 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: VIOME Precision Nutrition Program
Description: Diet and supplements recommendations
Study NCT00703274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT DC
Description: PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
Study NCT03028129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 900 milligrams
Description: Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
Study NCT03028129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
Study NCT01042587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exposure to bright light
Description: Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
Study NCT03537937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower SpO2 Target
Description: SpO2 target 90% (range 88-92%)
Study NCT04166916 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM acoustic stimulation
Description: This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 1
Description: Cereal products based on rye, barley, wheat, oat, and corn
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 2
Description: Cereal products based on rye, barley, wheat, oat, and corn
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 3
Description: Cereal products based on rye, barley, wheat, oat, and corn